Compositions and Methods for the Systemic Treatment of Arthritis
AssigneeBaylor Research Institute
InventorsJacques F. Banchereau, Maria Virginia Pascual
Life of this patent
Estimating the term…
Abstract
The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.
Claims24
A method for treating a joint with systemic onset juvenile idiopathic arthritis comprising administering to the joint a composition comprising a therapeutically effective amount of one or more active agents that reduces the bioavailability of interleukin-1β.
A method for treating a patient with systemic onset juvenile idiopathic arthritis comprising administering to the patient a composition comprising an effective amount of at least one agent capable of reducing or blocking the bioavailability of an interleukin-1β.
A method for treating a patient with systemic onset juvenile idiopathic arthritis comprising administering to the patient a composition comprising an effective amount of at least one agent capable of reducing or blocking the bioavailability of an interleukin-1β receptor.
A composition for treating SOJIA comprising a therapeutically effective amount of one or more active agents adapted for delivery to a joint that reduces the inflammation of the joint affected with SOJIA.
A pharmaceutical formulation comprising one or more active agents are selected from:
- one or more modifiers of interleukin-1 beta (IL-1β) gene transcription;
- one or more modifiers of IL-1β gene translation;
- one or more siRNAs that target the expression of IL-1β;
- one or more IL-1β receptors blockers;
- one or more interleukin-1 receptor antagonist proteins;
- one or more interleukin-1 receptor antagonist peptides;
- one or more active agents that modify the release of IL-1β;
- one or more antibodies that neutralize IL-1β;
- one or more antibodies that blocks an IL-1β receptor;
- one or more recombinant, naturally occurring IL-1 receptor antagonists;
- one or more anion transport inhibitors, lipoxins and alpha-tocopherol that inhibit the release of IL-1β;
- one or more opioids that inhibits a proteolytic enzyme that converts the inactive IL-1β 5precursor to its mature, active form;
- one or more antibodies that neutralizes the biological function of IL-1β, mixtures and combinations thereof adapted to treat joint autoinflammation.
A method of treating an animal suffering from an autoinflammation comprising administering a therapeutic agent to an animal suffering from autoinflammation, wherein that agent comprises an antagonist of Interleukin 1β function in a pharmaceutically acceptable carrier, wherein the antagonist suppresses the autoinflammation.
Dependencies are inferred from the claim text.